Ivermectin and COVID 19

World News

Ivermectin and COVID 19



Invitro antiviral activity

Against a broad range of viruses

HIV, dengue, influenza, Zika virus

Invitro antiviral, SARS-CoV-2 activity

99.8% reduction in viral RNA after 48 h

Worldwide use for treating COVID-19

About 3.7 billion doses of ivermectin have been distributed globally over the past 30 years



Preexposure prophylaxis in high-risk patients

Postexposure prophylaxis

Symptomatic patients at home

Mildly symptomatic patients in hospital

Progressive Respiratory symptoms

Ivermectin has emerged as the “wonder drug” to prophylaxis and treat COVID-19

Ivermectin inhibits viral replication and has potent anti-inflammatory properties

There is the potential for serious drug-drug interaction

Additional, studies are urgently required to confirm these very impressive preliminary findings

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 (7th December)


Front Line COVID-19 Critical Care Alliance (FLCCC)

One Sentence Summary

Review of recently available clinical trial results demonstrating efficacy of ivermectin in prophylaxis and treatment of COVID-19.

Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019

The ICON Study (October 2020, South Florida)


Research Question

Does ivermectin benefit hospitalized coronavirus disease 2019 (COVID-19) patients?

Study Design and Methods

Consecutive patients hospitalized

Four hospitals in Florida

Confirmed COVID-19

March 15 and May 11, 2020

Treated with or without ivermectin

Primary outcome

All-cause in-hospital mortality

Secondary outcomes, mortality in patients with severe pulmonary involvement, extubation rates for mechanically ventilated patients, length of stay

Severe pulmonary involvement

Need for Fio2 ≥ 50%, noninvasive ventilation

Invasive ventilation

Results from reviews

N = 280

Ivermectin treated = 173

Overall mortality 15%

Mortality with severe pulmonary involvement = 38.8%

Not given ivermectin = 107

Overall mortality 25% (OR, 0.52)

Mortality with severe pulmonary involvement = 80.7%

No significant differences were found in extubation rates or length of stay

Most patients in both groups also received hydroxychloroquine, azithromycin, or both


Ivermectin treatment was associated with lower mortality during treatment of COVID-19

Especially in patients with severe pulmonary involvement

Randomized controlled trials are needed to confirm these findings

Ivermectin news